← 홈

폐암 (NSCLC)

291개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 291개
ADCBiologicstaleDaiichi SankyoPhase 1

FL-DP (HER3-DXd, HER3-DXd (FL-DP))

Non-Small Cell Lung Cancer (NSCLC) · HER3

#HER3#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 56%임상시험 24상태 RECRUITING
AntibodystaleImmunityBio, Inc.Phase 2

Necitumumab (Necitumumab)

Squamous Cell Carcinoma · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 76%임상시험 23상태 DISCONTINUED
AntibodystalePfizerPhase 1

sasanlimab (sasanlimab)

Carcinoma, Pancreatic Ductal; Colorectal Neoplasms · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase1#항체#면역항체+5
효능 ORR 33.3%임상시험 23상태 DISCONTINUED
ADCBiologicstaleDaiichi SankyoPhase 1

CTM-1 Lyo-DP (HER3-DXd, HER3-DXd (CTM-1 Lyo-DP))

Non-Small Cell Lung Cancer (NSCLC) · HER3

#HER3#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 56%임상시험 22상태 RECRUITING
ADCBiologicstaleDaiichi SankyoPhase 1

CTM-3 Lyo-DP (HER3-DXd, HER3-DXd (CTM-3 Lyo-DP))

Non-Small Cell Lung Cancer (NSCLC) · HER3

#HER3#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 56%임상시험 22상태 RECRUITING
AntibodystaleAstraZenecaPhase 2

Monalizumab (Monalizumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2
효능 ORR 23.9%임상시험 22상태 RECRUITING
AntibodystaleMerckPhase 3

pembrolizumab (Keytruda, Pembrolizumab [KEYTRUDA®])

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) · Metastatic Cancer

#MetastaticCancer#Antibody#Phase3#항체#면역항체+4
효능 ORR 40%임상시험 22상태 DISCONTINUED
CGTBiologicstaleShanghai Yunying Medical Techno…Phase 1

R130 (Recombinant oncolytic herpes simplex virus type 1, Recombinant oncolytic herpes simplex virus type 1 (R130))

Lung Cancer; Bronchial Cancer · Sarcoma

#Sarcoma#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 21상태 ACTIVE
ADCBiologicstaleBioNTech SEPhase 3

Pumitamig (Pumitamig)

Non-small Cell Lung Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 19상태 RECRUITING
CGTBiologicChongqing Precision Biotech Co.…Phase 1

Targeted CEA CAR-T (Targeted CEA CAR-T)

Advanced Lung Cancer · CEA

#CEA#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 19상태 RECRUITING
ADCBiologicstaleAstraZenecaPhase 3

Volrustomig (Volrustomig)

Metastatic Non-small Cell Lung Cancer · Endometrial Cancer

#EndometrialCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 19상태 RECRUITING
AntibodyRochePreclinical

atezolizumab (Tecentriq, Atezolizumab+Bevacizumab+Carboplatin+Paclitaxel)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Preclinical#항체#면역항체+2
효능 ORR 88.7%임상시험 18상태 RECRUITING
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 3

Ifinatamab deruxtecan (Ifinatamab deruxtecan)

Prostate Cancer; Prostatic Neoplasms · Small Cell Lung Cancer

#SmallCellLungCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
임상시험 18상태 RECRUITING
ADCBiologicstaleAstraZenecaPhase 2

AZD5305 (Saruparib, Saruparib (AZD5305))

Ovarian Cancer; Lung Adenocarcinoma · Ovarian Cancer

#OvarianCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 18상태 RECRUITING
ADCBiologicstaleShanghai Junshi Bioscience Co.,…Phase 2

JS207 (JS207)

Non-squamous Non-small Cell Lung Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 15상태 RECRUITING
ADCBiologicstaleAstraZenecaPhase 2

Danvatirsen (Danvatirsen)

Advanced Colorectal Carcinoma; Advanced Lung Non-Small Cell Carcinoma · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 11.1%임상시험 14상태 RECRUITING
CGTBiologicstaleChongqing Precision Biotech Co.…Phase 1

Anti-CEA-CAR T (Anti-CEA-CAR T)

Lung Cancer; Colorectal Cancer · CEA

#CEA#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 13상태 ACTIVE
ADCBiologicstaleHoffmann-La RochePhase 3

Divarasib (Divarasib)

Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer · Solid Tumors

#SolidTumors#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
임상시험 13상태 RECRUITING
AntibodystaleStemcentrxPhase 1

Rovalpituzumab Tesirine (Rovalpituzumab Tesirine)

Small Cell Lung Carcinoma · Small Cell Lung Cancer

#SmallCellLungCancer#Antibody#Phase1#항체#면역항체+3
효능 ORR 27.6%임상시험 13상태 ACTIVE
ADCBiologicAbbVieadizutecanPhase 2

Telisotuzumab Adizutecan (Telisotuzumab Adizutecan)

Metastatic Colorectal Cancer · Non Small Cell Lung Carcinoma

#NonSmallCellLungCarcinoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 13상태 RECRUITING

4 / 15 페이지

← 이전다음 →